Table 2.
Incidence rates, hazard ratios and competing risk of active TB associated with Fluticasone/salmeterol relative to Budesonide/formoterol in patients with COPD in intent-to-treat and as treated analysis
| Fluticasone/salmeterol cohort | Budesonide/formoterol cohort | Crude HR (95%CI) | Adjustedb HR (95%CI) | Competing risk subHR (95%CI) |
|||||
|---|---|---|---|---|---|---|---|---|---|
| event | Person-Year | IRa | event | Person-Year | IRa | ||||
| ITT analysis | |||||||||
| Before propensity score matching | |||||||||
| TB | 358 | 38,123.37 | 0.94% | 175 | 28,559.41 | 0.61% | 1.50 (1.26–1.80) | 1.41 (1.17–1.70) | 1.45 (1.21–1.74) |
| After propensity score matching | |||||||||
| TB | 247 | 27,392.73 | 0.90% | 172 | 27,689.85 | 0.62% | 1.34 (1.07–1.69) | 1.45 (1.14–1.85) | 1.44 (1.19–1.75) |
| As treated analysis | |||||||||
| Before propensity score matching | |||||||||
| TB | 126 | 14,256.75 | 0.88% | 66 | 10,120.93 | 0.65% | 1.32 (0.98–1.78) | 1.28 (0.94–1.73) | 1.27 (0.94–1.71) |
| After propensity score matching | |||||||||
| TB | 85 | 9512.25 | 0.89% | 66 | 9872.11 | 0.67% | 1.23 (0.73–2.07) | 1.38 (0.79–2.42) | 1.31 (0.95–1.81) |
aIR Incidence rate
bAdjusted for age, gender, propensity score